ResMed (NYSE: RMD) reported Q3 EPS of $2.37, $0.02 worse than the analyst estimate of $2.39. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.29 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.